compound introduction
R-268712 是一种口服有效的选择性 ALK-5 抑制剂，其 IC50 值为 2.5 nM。R-268712 能以剂量依赖的方式抑制 Smad3 的磷酸化，其 IC50 值为 10.4 nM。R-268712 通过抑制TGF-β 的信号传导来抑制肾小球肾炎以及肾小球硬化，可用于肾脏纤维化和癌症的研究。 R-268712 is an orally active and selective ALK-5 inhibitor, with an IC50 of 2.5 nM. R-268712 inhibits the phosphorylation of Smad3 in a dose-dependent manner with an IC50 of 10.4 nM. R-268712 suppresses glomerulonephritis as well as glomerulosclerosis by inhibiting TGF-β signaling, which can be used in studies of renal fibrosis and cancer.
